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Metabolic Effects of Hepatic Replacement in Wilson's Disease 
By Carl G. Groth, Reuben S. Dubois, Jacques Corman, Ake Gustafsson, 
Shunzaburo Iwatsuki, Denis O. Rodgerson, Charles G. Halgrimson, and Thomas E. Starzl 
W ILSON's disease is an inborn disorder 
of metabolism characterized by pro-
gressive accumulation of copper in tissues 
with subsequent degenerative changes that 
affect mainly the brain and the liver. Dis-
coloration of the cornea by the metal is 
observable on split-lamp examination as 
the Kayser-Fleischer ring. Abnormal bio-
chemical findings may include elevated al-
bumin-bound serum copper, increased uri-
nary excretion of copper, low level of the 
copper-containing serum protein cerulo-
plasmin, and low total serum copper. The 
nature of the primary metabolic defect re-
mians obscure. 1 
The frequency and significance of severe 
hepatic involvement in Wilson's disease 
has become increasingly apparent in the 
last years.2 ,3 Clinically, the hepatic dis-
order is indistinguishable from other forms 
of chronic hepatitis. Histologically, there 
is "postnecrotic" cirrhosis with alcoholic 
hyaline bodies of Mallory. 
Two teen-age boys with liver cirrhosis 
due to Wilson's disease have been treated 
with orthotopic hepatic transplantation at 
our institution. Studies of the copper me-
tabolism in these patients has provided 
important information concerning the role 
of the liver in Wilson's disease. 
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CASE REPORTS 
Patient No.1: An ll-yr-old boy was ad-
mitted for hepatic transplantation in July 1969. 
His liver disease dated back to the age of 8 when 
he was found to have abnormal liver-function 
tests and a liver biopsy showed "postnecrotic" 
cirrhosis. In April 1969 he developed symptoms 
of hepatiC failure. A liver biopsy showed cirrhosis 
with Mallory bodies; the findings were inter-
preted as being consistent with Wilson's disease. 
There were no neurological symptoms and no 
Kayser-Fleischer rings. Two months later the 
patient was transferred to our institution in pre-
coma. At this time he had massive ascites and 
anasarca. The serum bilirubin was 20.6 mg/IOO 
ml, the serum albumin 1.5/100 ml, the pro-
thrombin time 13% of normal, and blood am-
monia 432 Ilg nitrogen/l00 ml. A few hours after 
arrival the patient developed upper gastrointesti-
nal hemorrhage and became agonal. Shortly after-
ward a cadaveric donor became available and 
the patient underwent an orthotopic hepatic trans-
plantation.4 Posttransplantation immunosuppres-
sion included azathioprine or cyclophosphamide, 
prednisone, and antilymphocyte globulin4 ,5 (Fig. 
1). 
After the operation there was a clearing of 
the sensorium and a fall in the blood ammonia 
level. The serum bilirubin diminished (Fig. 1), 
and total serum protein and the prothrombin time 
normalized. Two early rejection episodes occurred. 
At the time of the second, there was an extreme 
degree of hyperbilirubinemia and alkaline phos-
phatmia (Fig. 1). Reversal of the rejection was 
followed by 1 yr of normal graft function but in 
the succeeding years there has been moderate 
elevation of SePT and some episodes of hyper-
bilirubinemia (Fig. 1). Presently, 3 yr 2 mo after 
transplantation, the bilirubin is 2.2 mg/lOO ml, 
alkaline phosphatase is 292 IU, and sePT is 
210 IU. Tests for Australia antigen in serum has 
conSistently been negative. The patient is clin-
ically well. No dietary limtations have been im-
posed and chelating agents have never been 
administered except for two brief tests. 
Patient No.2. This boy was admitted in 
March 1971 at the age of 14 yr for hepatic trans-
plantation. At 11 yr of age liver disease had 
been diagnosed when he presented with ascites 
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Fig. 1. The course in the first patient. 
and a serum bilirubin of 9.5 mg/IOO m!. In the 
next year there was an improvement but at 13 
yr he had two episodes of hematemesis. At this 
time there was moderate neurological involvement 
with tremor and athetotic movements. Split-lamp 
examination revealed Kayser-Fleischer rings. An 
open liver biopsy showed postnecrotic cirrhosis. 
The finding of an elevated copper content in the 
liver specimen as well as typical abnormalities in 
the serum and urine copper established the diag-
nosis of Wilson's disease. A low-copper diet was 
instituted and chelating therapy was attempted 
initially with D-penicillamine and later with 
triethylene tetramine dihydrochloride. In spite of 
increased cupriuresis the patient's neurological 
status deteriorated and he became severely 
crippled with chorea and dysarthria. 
At the time of transplantation the serum bili-
rubin was 2.9 mg/IOO m!, serum albumin was 
2.9 g/IOO ml, and prothrombin time 44% of 
normal. Postoperative immunosuppression was as 
in the first patient except that cyclophosnhamide 
was given instead of azathioprine during the first 
9 rna (Fig. 2). After 1 mo of normal graft function 
there was a sudden rise in the serum bilirubin 
(maximum 9.6 mg/IOO ml), the alkaline phos-
phatase (maximum 952 IU), and the SGPT (maxi-
mum 300 IU) (Fig. 2). The concurrent development 
of Australia antigenemia suggested serum hepa-
titis. Over the next few months liver function 
became normal (Fig. 2). Presently, 17 rna after 
transplantation, serum bilirubin is 0.64 mg/IOO ml, 
alkaline phosphatase is 94 IU, and SGPT 30 IU, 
all within normal limits of our laboratory. 
After transplantation the chelating therapy was 
not resumed and the dietary limitation in copper 
intake was abolished. 
During the first 12 rna postoperative the pa-
tient's neurological status was intermittently im-
proved but in intervening periods chorea and 
dysarthria was prominent. On the most recent 
neurological evaluation 17 mo after operation a 
definite improvement was noted, although the 
symptoms had not cleared completely. 
Repeated examinations of the corneas showed 
unchanged Kayser-Fleischer rings during the first 
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Fig. 2. The course in the second patient. 
12 mo of postoperative follow-up. At 17 mo, 
however, a distinct decrease in coloration was 
noted. 
STUDIES OF THE COPPER 
METABOLISM 
Liver Copper: The diseased native livers both 
had an abnormally high copper content. The 
copper concentration in the removed liver of the 
first patient was 216 pg/g wet weight (normal < 
20 ,ug). In the second patient a biopsy specimen 
obtained 12 mo before transplantation contained 
329 Pg copper/g wet weight. After therapy with 
chelating agents the removed liver contained 
184 p.gl g wet weight. 
Biopsy specimens of the hepatic homograft ob-
tained in the first patient at 6, 17, and 28 mo 
after transplantation contained 15, 13, and 17 /Lg 
of copper/g wet weight. Histopathologically, 
these tissues had minor abnormalities as previ-
ously reported.6 In the second patient the liver 
copper concentration was 48, 30, and 45 p.g in 
biopsy specimens obtained after 12, 13, and 17 
mo, respectively. Histopathologically, these liver 
specimens were normal. 
Urinary Copper Excretion: The first patient 
had normal urinary copper excretion when studied 
at another hospital several months before trans-
plantation. In contrast, the second patient had an 
elevated copper excretion of 340 I'g 24 hr (normal 
< 30 I'g) before institution of chelating therapy. 
At the time of transplantation when chelating 
agent had been given for 1 yr 540 I'g was excreted 
in 24 hI. 
During the first several months after the hepatic 
replacement, the urinary copper excretion in-
creased to high levels in the first patient and it 
remained elevated in the second patient. After 
approximately 5 mo a decrease toward normal 
was noted in both patients (Figs. 1 and 2). In the 
last year the first patient has occasionally ex-
created increased amounts of copper (maximum 
225 I'g/24 hr) (Fig. 2). 
A 3-day course of D-penicillamine (1.5 g/day) 
given to the first patient at 7 and again at 35 mo 
after transplantation increased the copper excre-
tion to 974 and 770 /Lg/24 hr, respectively, A 
similar test in the second patient at 12 mo post-
transplantation resulted in an excretion of 646 p.g, 
as compared with 1412 I'g/24 hr 1 yr before the 
operation. 
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Serum Ceruloplasmin and Copper: In the first 
patient, preoperative serum ceruloplasmin was 
within normal range except for one sample in 
which it was diminished to 15 mg/lOO ml (normal 
22-43 mg/lOO ml). Serum copper was normal in 
one specimen obtained at a previous admission to 
another hospital. In the seond patient serum 
ceruloplasmin was almost absent with concen-
trations of 1.0-1.7 mg/lOO ml, and total serum 
copper concentration was low at 22.4-35 Itg/lOO 
ml (normal 70-118 Itg). 
After hepatic transplantation serum cerulo-
plasmins and total serum coppers have been 
normal or slightly above normal during the 3 yr 
2 mo of follow-up in the first patient (Fig. 1). In 
the second patient, these measures rose within 
the first weeks after transplantation to reach 
normal levels. The levels have been subsequently 
within or above normal range (Fig. 2). 
DISCUSSION 
The early work-up of the first patient 
had revealed postnecrotic cirrhosis with 
Mallory bodies suggesting Wilson's dis-
ease, but the lack of neurologic impairment 
and the absence of Kayser-Fleischer rings 
as well as the normal serum ceruloplasmin 
and copper made the diagnosis equivocal. 
As a consequence, chelating therapy was 
never instituted in spite of the progressive 
deterioration in liver function. When the 
patient presented at our institution his 
condition was no longer amenable to med-
ical treatment and hepatic transplantation 
was carried out.6 
The second patient had all the classical 
clinical and biochemical manifestations of 
Wilson's disease. Consequently, low-copper 
diet and therapy with chelating drugs had 
been tried for more than 1 yr. During this 
time the liver copper decreased somewhat 
but there was no evidence of corollary 
improvement in hepatic function. Further-
more, the patient's chorea and dysarthria 
progressed to a stage where he was severely 
crippled. When hepatic transplantation was 
carried out it was hoped that the provision 
of a normal liver would improve the copper 
metabolism with consequent amelioration 
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of the extrahepatic manifestations of the 
disease. 
Several findings indicate that the han-
dling of copper was indeed favorably af-
fected by the hepatic replacement. There 
was no accumulation of the metal in the 
new liver of the first patient. In the second 
patient, the serum ceruloplasmin and cop-
per normalized shortly after transplanta-
tion and biopsy specimens of the graft 
have shown only a slightly elevated copper 
concentration. The initial high urinary ex-
cretion of copper is consistent with clearing 
of tissue copper stores, although both pa-
tients had concurrent hepatic dysfunction 
with cholestasis which might interfere with 
biliary excretion of copper and cause a 
compensatory capriuresis. When later in 
the course D-penicillamine was admin-
istered over 3 days, both patients showed a 
copper excretion only slightly exceeding 
that seen in normal persons. Finally, the 
fact that the neurologic symptoms have 
abated and that the Kayser-Fleischer rings 
have become less prominent in the second 
patient indicates that the extrahepatic mani-
festations are being favorably affected by 
the hepatic transplantation. The present 
findings are consistent with the hypothesis 
that the metabolic defect in Wilson's dis-
ease is liver based. Hopefully, the future 
course of these two patients will provide 
grounds for a definite conclusion concern-
ing the role of the liver in the pathogenesis 
of the disease. 
SUMMARY 
Two boys with Wilson's disease had liver 
replacement 3 and 11/2 yr ago for terminal 
hepatic failure and moderate cirrhosis plus 
severe neurologic involvement, respectively. 
Both patients had a high liver copper value 
but only the second boy had low cerulo-
plasma and total serum copper and in-
creased urinary copper excretion. Biopsy 
specimen of the grafts have shown copper 
WILSON'S DISEASE 
levels that are normal or only slightly ele-
vated. The serum and urine findings in the 
second patient have normalized, his neuro-
logic symptoms have abated, and the Kay-
833 
ser-Fleischer rings have become less promi-
nent. The findings are consistent with the 
hypothesis that the metabolic defect in 
Wilson's disease is liver based. 
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